# A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

> **NCT02576431** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 215 (actual)

## Conditions studied

- Solid Tumors Harboring NTRK Fusion

## Interventions

- **DRUG:** BAY2757556 (Larotrectinib, Vitrakvi)

## Key facts

- **NCT ID:** NCT02576431
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-30
- **Primary completion:** 2025-09-29
- **Final completion:** 2025-09-29
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576431, "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02576431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*